Bristol Getting Eagerly Awaited First-Line Opdivo Lung Data Earlier Than Expected

Bristol-Myers Squibb Co. is moving up the timing on its eagerly awaited CheckMate-026 first-line lung cancer trial of Opdivo, with data now expected in the third quarter – earlier than prior guidance.